1M. Shibuya,Y. Suzuki,K. Sugita,I. Saito,T. Sasaki,K. Takakura,S. Okamoto,H. Kikuchi,T. Takemae,H. Hidaka. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage[J] 1990,Acta Neurochirurgica(1-2):11～15
2M. Shibuya,Y. Suzuki,M. Takayasu,T. Asano,T. Harada,I. Ikegaki,S. Satoh,H. Hidaka. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs[J] 1988,Acta Neurochirurgica(1-2):53～59
2Zhang Z X, Zahner G E, Roman G C, et al. Dementia sub- types in China: prevalence in Beijing, Xian, Shanghai, and Changdu [ J ]. Arch Neurol, 2005, 62 (3) : 447.
3Yanpallewar S U, Hota D, Rai S, et al. Nimodipine attenu atea biochemical, behavioral and histopathological alterations induced by acute transient and long - term bilateral connon carotid occlusion in rats[ J ]. Pharmaeol Re.s, 2004, 49 (2) : 143.
4龚耀先.中国修订《韦氏成人智力量表手册》[M].湖南地图出版社,1992.
5Pantoni L, Bianchi C, Beneke M, et al. The Scandinavian Multi infarct Demenita trial: a double- bilnd, placebo- controlled trail on nimodipine in multi infarct dementia[J ]. J Neurol Sci, 2000, 175(2): 116.
6Kavirajan H, Schneider L S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta analysis of randomised controlled trials [ J ]. Lancet Neurol, 2007, 6(9): 782.
